Sugi Predict

Sugi Predict / Compounds / SCHEMBL2179544

SCHEMBL2179544

SCHEMBL2179544

Cc1cc([N+](=O)[O-])c(O)nc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR35 Q9HC97 3/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ CYP1A2 P05177 1/20 0.43
▸ GALR2 O43603 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ SNCA P37840 1/20 0.40
▸ TSHR P16473 4/20 0.40
▸ HSD17B10 Q99714 1/20 0.39
▸ HSP90AA1 P07900 2/20 0.39
▸ CTSB P07858 1/20 0.39
▸ CTSH P09668 1/20 0.39
▸ HSP90AB1 P08238 1/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ RECQL P46063 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ CCR6 P51684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1558145 0.85 GPR35 (0.47) GPR35ALDH1A1CYP1A2POLBTSHR
SCHEMBL8801989 0.82 CYP1A2 (0.47) GPR35ALDH1A1CYP1A2GALR2LMNA
SCHEMBL16321777 0.81 GPR35 (0.44) GPR35ALDH1A1CYP1A2GALR2LMNA
SCHEMBL16563437 0.79 ALDH1A1 (0.46) GPR35ALDH1A1LMNAPOLBHSD17B10
SCHEMBL25624226 0.77 CYP1A2 (0.52) GPR35ALDH1A1CYP1A2GALR2LMNA
SCHEMBL28825412 0.77 ALDH1A1 (0.47) GPR35ALDH1A1CYP1A2GALR2LMNA
SCHEMBL30946653 0.77 CYP1A2 (0.43) GPR35ALDH1A1CYP1A2GALR2LMNA
SCHEMBL217060 0.77 CYP1A2 (0.43) GPR35ALDH1A1CYP1A2GALR2LMNA
SCHEMBL24779889 0.76 PDGFRB (0.45) GPR35ALDH1A1CYP1A2LMNAPOLB
SCHEMBL1200517 0.76 GPR35 (0.46) GPR35ALDH1A1CYP1A2GALR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3743068-B1 COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS EXELIXIS INC (US) 2026-04-29 — — EP disclosed
US-12195475-B2 Compounds for the treatment of kinase-dependent disorders EXELIXIS, INC. (US) 2025-01-14 — — US disclosed
CN-112312909-B Compounds for the treatment of kinase dependent disorders 埃克塞里艾克西斯公司 2024-07-02 — — CN disclosed
US-20230374024-A1 Compounds for the Treatment of Kinase-Dependent Disorders EXELIXIS, INC. 2023-11-23 — — US disclosed
US-20230374024-A1 Compounds for the Treatment of Kinase-Dependent Disorders EXELIXIS, INC. 2023-11-23 — — US disclosed
US-11708367-B2 Compounds for the treatment of kinase-dependent disorders EXELIXIS, INC. (US) 2023-07-25 — — US disclosed
US-11708367-B2 Compounds for the treatment of kinase-dependent disorders EXELIXIS, INC. (US) 2023-07-25 — — US disclosed
US-20210040099-A1 Compounds for the Treatment of Kinase-Dependent Disorders EXELIXIS, INC. 2021-02-11 — — US disclosed
CN-112312909-A Compounds for the treatment of kinase-dependent disorders 埃克塞里艾克西斯公司 2021-02-02 — — CN disclosed
EP-3743068-A1 COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS Exelixis, Inc. (US) 2020-12-02 — — EP disclosed
US-8501770-B2 Substituted imidazopyridinyl-aminopyridine compounds ARQULE, INC. (US) 2013-08-06 — — US disclosed
US-8501770-B2 Substituted imidazopyridinyl-aminopyridine compounds ARQULE, INC. (US) 2013-08-06 — — US disclosed
US-8501770-B2 Substituted imidazopyridinyl-aminopyridine compounds ARQULE, INC. (US) 2013-08-06 — — US disclosed
CN-102781940-A Substituted imidazopyridinyl-aminopyridine compounds ARQULE INC 2012-11-14 — — CN disclosed
EP-2519522-A2 SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS ArQule, Inc. (US) 2012-11-07 — — EP disclosed
US-20110172203-A1 Substituted Imidazopyridinyl-Aminopyridine Compounds ARQULE, INC. (US) 2011-07-14 — — US disclosed
US-20110172203-A1 Substituted Imidazopyridinyl-Aminopyridine Compounds ARQULE, INC. (US) 2011-07-14 — — US disclosed
US-20110172203-A1 Substituted Imidazopyridinyl-Aminopyridine Compounds ARQULE, INC. (US) 2011-07-14 — — US disclosed
WO-2011082270-A2 SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS ARQULE. INC. (US) 2011-07-07 — — WO disclosed
WO-2011082270-A2 SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS ARQULE. INC. (US) 2011-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708367-B2 Compounds for the treatment of kinase-dependent disorders ERBB2, ERBB3, MAP3K6 GPR35 1948/4885ALDH1A1 3215/4885CYP1A2 3994/4885
US-20210040099-A1 Compounds for the Treatment of Kinase-Dependent Disorders ERBB2, ERBB3, MAP3K6 GPR35 1948/4885ALDH1A1 3215/4885CYP1A2 3994/4885
US-20230374024-A1 Compounds for the Treatment of Kinase-Dependent Disorders ERBB2, ERBB3, MAP3K6 GPR35 1948/4885ALDH1A1 3215/4885CYP1A2 3994/4885
US-12195475-B2 Compounds for the treatment of kinase-dependent disorders ERBB2, ERBB3, MAP3K6 GPR35 1948/4885ALDH1A1 3215/4885CYP1A2 3994/4885
US-20110172203-A1 Substituted Imidazopyridinyl-Aminopyridine Compounds MKI67, CDK4, ABL1 GPR35 2417/4885ALDH1A1 651/4885CYP1A2 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback